Wim Timens Selected Research

Immunotherapy

4/2024	The neo-open reading frame peptides that comprise the tumor framome are a rich source of neoantigens for cancer immunotherapy.
3/2024	Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.
3/2024	Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
12/2022	Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial.
1/2022	The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer.
11/2021	Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
1/2021	Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
7/2020	Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer.
5/2016	PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wim Timens Research Topics

Disease

106	Chronic Obstructive Pulmonary Disease (COPD) 02/2024 - 10/2003
35	Asthma (Bronchial Asthma) 11/2023 - 06/2005
34	Inflammation (Inflammations) 07/2022 - 08/2002
22	Neoplasms (Cancer) 04/2024 - 11/2002
22	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 11/2002
16	Emphysema 01/2021 - 07/2003
12	Lung Neoplasms (Lung Cancer) 11/2020 - 05/2006
11	Lung Diseases (Lung Disease) 04/2024 - 08/2004
6	Airway Remodeling 01/2022 - 01/2013
5	Fibrosis (Cirrhosis) 04/2024 - 07/2006
4	Adenocarcinoma of Lung 11/2021 - 12/2010
4	COVID-19 06/2021 - 01/2020
4	Respiratory Hypersensitivity 01/2021 - 06/2004
3	Disease Progression 03/2024 - 01/2008
3	Obstructive Lung Diseases (Obstructive Lung Disease) 01/2023 - 11/2012
3	Adenocarcinoma 02/2022 - 01/2011
3	Pneumonia (Pneumonitis) 01/2016 - 01/2008
3	Airway Obstruction (Choking) 10/2015 - 07/2006
2	Idiopathic Pulmonary Fibrosis 02/2024 - 05/2023
2	Systemic Scleroderma (Systemic Sclerosis) 11/2023 - 01/2023
2	Pulmonary Arterial Hypertension 01/2023 - 11/2020
2	Chronic Bronchitis 01/2020 - 11/2005
2	Vascular Remodeling 01/2016 - 03/2015
2	Chronic Disease (Chronic Diseases) 01/2013 - 01/2011

Drug/Important Bio-Agent (IBA)

30	Proteins (Proteins, Gene)FDA Link 04/2024 - 11/2002
29	SmokeIBA 01/2022 - 07/2003
23	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 01/2007
14	CytokinesIBA 11/2023 - 08/2002
13	Biomarkers (Surrogate Marker)IBA 04/2024 - 05/2013
12	Messenger RNA (mRNA)IBA 01/2021 - 03/2004
10	CollagenIBA 11/2023 - 01/2009
10	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2013
9	SteroidsIBA 01/2023 - 10/2009
8	RNA (Ribonucleic Acid)IBA 02/2024 - 01/2020
8	DecorinIBA 01/2021 - 03/2005
7	GoldIBA 01/2020 - 12/2008
7	Fluticasone (Cutivate)FDA LinkGeneric 01/2019 - 10/2009
7	multidrug resistance-associated protein 1IBA 12/2012 - 06/2005
6	LigandsIBA 11/2023 - 08/2003
5	InterleukinsIBA 01/2020 - 07/2005
4	Anaplastic Lymphoma KinaseIBA 01/2023 - 12/2010
4	B7-H1 AntigenIBA 01/2022 - 10/2019
4	Bronchodilator Agents (Bronchodilators)IBA 01/2021 - 03/2011
4	OvalbuminIBA 01/2016 - 08/2002
4	Interleukin-8 (Interleukin 8)IBA 01/2016 - 04/2005
4	Adenosine Monophosphate (AMP)IBA 01/2015 - 06/2008
3	Peptides (Polypeptides)IBA 04/2024 - 09/2013
3	ChemokinesIBA 11/2023 - 07/2007
3	Immune Checkpoint InhibitorsIBA 12/2022 - 11/2021
3	AntibodiesIBA 11/2022 - 04/2006
3	Formaldehyde (Formol)FDA Link 11/2022 - 10/2020
3	DNA (Deoxyribonucleic Acid)IBA 03/2022 - 01/2017
3	ElastinIBA 02/2022 - 11/2009
3	Interleukin-6 (Interleukin 6)IBA 01/2021 - 07/2005
3	Angiotensin-Converting Enzyme 2IBA 12/2020 - 01/2020
3	Transforming Growth Factor beta (TGF-beta)IBA 11/2020 - 12/2008
3	GasesIBA 01/2020 - 01/2009
3	Proteoglycans (Proteoglycan)IBA 01/2018 - 12/2008
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2013 - 07/2006
3	AntigensIBA 08/2012 - 04/2006
2	Interleukin-33IBA 11/2023 - 01/2016
2	GlucocorticoidsIBA 01/2023 - 11/2015
2	Vasodilator Agents (Vasodilators)IBA 01/2023 - 01/2021
2	Receptor for Advanced Glycation End ProductsIBA 01/2023 - 01/2021
2	ParaffinIBA 11/2022 - 10/2020
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2022 - 06/2011
2	Tyrosine Kinase InhibitorsIBA 10/2022 - 12/2019
2	Circulating Tumor DNAIBA 11/2021 - 11/2021
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021 - 01/2011
2	Interleukin-10 (Interleukin 10)IBA 01/2021 - 12/2011
2	ParaquatIBA 01/2021 - 01/2020
2	Cholinergic Agents (Cholinergics)IBA 01/2021 - 01/2020
2	Serine Proteases (Serine Protease)IBA 12/2020 - 11/2020
2	Budesonide (Pulmicort)FDA LinkGeneric 10/2020 - 01/2013
2	Interleukin-1 (Interleukin 1)IBA 01/2020 - 01/2017
2	Phosphodiesterase 4 InhibitorsIBA 01/2020 - 10/2003
2	AllergensIBA 12/2019 - 07/2006
2	Laminin (Merosin)IBA 12/2019 - 01/2009
2	Chemokine ReceptorsIBA 03/2019 - 03/2004
2	ErbB Receptors (EGF Receptor)IBA 03/2019 - 12/2010
2	Interleukin-17 (Interleukin 17)IBA 01/2019 - 07/2005
2	CrizotinibIBA 01/2018 - 01/2016
2	Fluticasone-Salmeterol Drug Combination (Advair)FDA Link 01/2017 - 11/2012
2	Phosphotransferases (Kinase)IBA 11/2015 - 06/2011
2	Nicotine FDA Link 10/2015 - 01/2012
2	CateninsIBA 01/2015 - 01/2011
2	erythromycin propionate-N-acetylcysteinateIBA 11/2014 - 01/2012
2	Transforming Growth Factors (Transforming Growth Factor)IBA 10/2013 - 12/2011
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2013 - 12/2009
2	AutoantibodiesIBA 08/2012 - 12/2010
2	Interleukin-13IBA 12/2011 - 06/2008
2	Fibronectins (Fibronectin)IBA 01/2011 - 03/2005
2	Purinergic P1 Receptors (Adenosine Receptor)IBA 03/2009 - 06/2008
2	Adenosine (Adenocard)FDA LinkGeneric 03/2009 - 06/2008
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 03/2009 - 03/2004

Therapy/Procedure

33	Therapeutics 04/2024 - 10/2003
9	Immunotherapy 04/2024 - 05/2016
3	Drug Therapy (Chemotherapy) 10/2022 - 04/2015
3	Lung Transplantation 04/2009 - 08/2004
2	Lasers (Laser) 12/2023 - 05/2011